



REVOLUTIONARY CANCER RELAPSE DETECTION IN A SIMPLE BLOOD TEST

NON-INVASIVE | PAIN FREE | INNOVATIVE

Aspect Liquid Biopsy supports targeted treatment decisions by detecting cancer recurrence earlier using cfDNA biomarkers through an innovative yet simple blood test.

Visit our website to learn more
clinicallabs.com.au/aspect

AUSTRALIAN
 **Clinicallabs**



Australian Clinical Labs is the first national private laboratory in Australia to introduce the innovation of liquid biopsy.

Aspect Liquid Biopsy uses the latest technology to analyse a bio-fluid sample to assess the genetic makeup of a tumour. The process for patients is the same as a standard blood test which is non-invasive and pain free, saving time and money without the need to undergo an invasive procedure or hospital admission.

Why is liquid biopsy so important?

Unlike traditional biopsies which can be invasive, painful and require recovery time, Aspect Liquid Biopsy is a non-invasive, simple blood test which can be used to monitor cancers including melanoma, lung and colorectal using cell-free DNA biomarkers in blood.

Earlier detection can support better treatment decisions. Aspect Liquid Biopsy can improve patient outcomes and increase survival rates by detecting cancer recurrence earlier than the current conventional methods, such as imaging, invasive techniques and blood tumour markers.

Cancer genetic profile in a simple blood test

Aspect Liquid Biopsy has been made possible by advances in sequencing the human genome. Using the tumour-derived circulating DNA, Aspect Liquid Biopsy allows the detection of the tumour somatic mutations that commonly occur in cancers, enabling the identification of the actionable gene targets (e.g. *EGFR* in lung cancer, *KRAS* in colorectal and *BRAF* in melanoma), thus correlating with clinical parameters and facilitating monitoring and treatment selection.



Supporting the most effective treatment decisions.

After a traditional biopsy, a tissue sample taken may not contain tumour tissue, or may not qualify for DNA mutation testing due to degraded DNA quality, or an insufficient quantity to run the assay.

Over time, resistant clones containing other variants may grow out of the tumour - variants that were not detected from the initial solid tissue biopsy. This makes the genetic makeup of the original tumour historical.

Aspect Liquid Biopsy enables the discovery of those new DNA markers in the blood in real time, supporting the most effective treatment decisions.

“A Personalised Medicine approach in cancer care is not new. What is new, however, is our ability to predict cancer recurrence based on the differences between individuals at molecular levels. This means that we can sub-group, or sub-stratify patients in a more meaningful way, with the potential to modify therapeutic regimes to match their individual genetic profile.”

Assoc. Prof. Mirette Saad

MBBS (HONS), MD (HONS), MAACB, FRCPA, PHD

**National Clinical Director of Molecular Genetic Pathology,
Australian Clinical Labs**

P: (03) 9538 6777

E: Mirette.Saad@clinicallabs.com.au

Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Clinical Director of Molecular Genetic Pathology at Australian Clinical Labs. Associate Professor Saad's PhD research allowed her to gain unique experience in a wide range of biochemical, molecular genetics and cancer targeting. She has published several articles both locally and internationally. At Clinical Labs, Assoc. Prof Mirette Saad leads the Molecular Genetic testing for hereditary disorders, personalised drug therapy, somatic mutation and gene expression profile testing in cancer.



How to order

Health Practitioners can order Aspect Liquid Biopsy for cancer patients using the Aspect request form. Some required information is listed on the form, including the type of cancer, whether it is a new diagnosis and if the patient is on anti-tumour therapy (if known). Health Practitioners can download the Aspect Liquid Biopsy form on the Clinical Labs website at clinicallabs.com.au/aspect

When should it be ordered?

Health Practitioners can order Aspect Liquid Biopsy for cancer patients any time during management stages.

What is the cost?

Out of pocket fee of \$550.
(No Medicare rebate available)

When will results be available?

Results will be available after 5-7 business days from the sample receipt date.

How is it collected?

This test requires two 10ml blood samples which can be taken at any of our collection centres.

Visit our website to learn more
clinicallabs.com.au/aspect



The word *aspect* is defined as a unique view or perspective. Through Aspect Liquid Biopsy, we can offer an unprecedented view of the genetic signatures of cancer relapse, allowing clinicians to catch it early and make the most effective treatment decisions.

Advanced Technology

Highly Sensitive and Specific Assay

Expertise in Diagnostic Oncology

Accurate and Comprehensive Reports

High-Quality, Personalised Cancer Care

Rapid Turnaround Time



VISIT OUR WEBSITE TO LEARN MORE
CLINICALLABS.COM.AU/ASPECT

1. Fleischacker M *et al.*, (2007) *Biochem Biophys Acta* 1775; 181-232.
2. John T *et al.*, (2017) *Asia-Pacific J of Clin Oncol* 13; 296-303.

3. Thierry AR *et al.*, (2014) *Nat Med* 20; 430-35.
4. Newman AM *et al.*, (2014) *Nat Med* 20; 548-54.

5. Thress *et al.*, (2015) *Lung Cancer* 90; 509-15.
6. Wu YL *et al.*, (2017) *Br J cancer* 116; 175-85.

7. Tie *et al.*, (2016) *Sci Transl Med* 8; 346ra92.
8. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non-small cell lung cancer (7 April 2017)